Join Forces

Leverage a Fully-Integrated Immuno-Oncology Platform 


OncoSec is seeking investment or partnership in the following areas:

  • TAVO in advanced melanoma and triple negative breast cancer
  • TAVO in additional solid tumor indications
  • Early-stage discovery programs for immune-oncology
  • Single-domain antibody and pipeline immune-oncology directed antibodies
  • Technology access program


OncoSec Lead Program: TAVO

  • Registration-directed study in advanced melanoma in combination with pembrolizumab in patients progressing on an approved checkpoint inhibitor (PISCES/KEYNOTE-695): Currently Enrolling
  • Planned clinical trial will evaluate the safety and efficacy of the combination in patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC) who have previously failed at least one systemic chemotherapy or immunotherapy (OMS-141/KEYNOTE-890): In Progress
  • Potential to become the first marketed therapeutic to address the anti-PD-1 non-responder population
  • Fast track and orphan drug designations granted by the FDA
  • Data in melanoma and additional solid tumor indications show antigen-specific T-cell responses and conversion of “cold” to “hot”


OncoSec Pipeline Programs: A Modular System for Combinatorial Therapeutics

  • Multi-gene plasmid platform offers tunable expression of several genes from a single construct
  • Single-domain camelid antibody platform enables faster, less expensive antibody discovery with higher probability of success
  • Technology Access Program offers OncoSec technologies to partners for pre-clinical research


MerckOncoSec Medical Inc. entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of OncoSec’s TAVO and Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), a registered trademark of Merck Sharp & Dohme Corp. in a phase 2b clinical trial, referred to as PISCES/KEYNOTE-695.

Read More